Background The international practice guidelines for patients with acute cholangitis and cholecystitis were released in 2007 (TG07) and revised in 2013 (TG13). This study investigated updated epidemiology and outcomes among patients with acute cholangitis on a larger scale for the first time. Methods This is an international multi-center retrospective observational study in Japan and Taiwan. All consecutive patients older than 18 years of age and given a clinical diagnosis of acute cholangitis by clinicians between 1 January 2011 and 31 December 2012 were enrolled. Those who met the diagnostic criteria of acute cholangitis by TG13 were statistically analyzed. Results A total of 7,294 patients were enrolled and 6,433 patients met the TG13 diagnostic criteria. The severity distribution was Grade I (37.5%), Grade II (36.2%), and Grade III (26.2%). The 30-day all-cause mortality was 2.4%, 4.7%, and 8.4% in Grade I, II, III severity, respectively (P < 0.001). The incidence of liver abscess and endocarditis as complications of acute cholangitis was 2.0% and 0.26%, respectively. Conclusions This is the first large scale study to investigate patients with acute cholangitis. This study provides the basis to define the best practices to manage patients with acute cholangitis in future studies.
Introduction
Acute cholangitis is still a life-threatening infection if it is not appropriately diagnosed and treated in a timely fashion [1] . International practice guidelines for acute cholangitis and cholecystitis were developed and released in 2007 as Tokyo Guidelines 2007 (TG07) [2] and revised in 2013 as Tokyo Guidelines 2013 (TG13) [3] . The mainstay of the management of acute cholangitis includes endoscopic or percutaneous biliary drainage and antimicrobial therapy [4] [5] [6] . Over the past decade, significant progress has been made with the development of medical technology in managing patients with acute cholangitis. Endoscopic technique for biliary drainage has made rapid progress [7] . Along with this development, antimicrobial resistance among Gram-negative causative organisms has spread so extensively that all healthcare professionals should be aware of these global threats and utilize antimicrobial agents very prudently and wisely [8, 9] . However, despite newer biliary drainage techniques, increasing antimicrobial resistance, and increasing number of elderly patients with multiple medical problems in many areas of the world, clinically updated and comprehensive epidemiological data on patients with acute cholangitis have been very limited [10] . Recent available data on patients with acute cholangitis have been on relatively small cohorts of patients from single institutions or a small number of institutions [11] [12] [13] [14] [15] [16] . In Europe, prospective studies on patients with complicated intra-abdominal infections have been performed and published [17, 18] . In these studies, however, patients with acute cholangitis have not been specifically targeted. Given these limited epidemiological data, the present study was conducted to update and provide comprehensive demographic epidemiology, microbiology, and outcomes among patients with acute cholangitis from multiple institutions on a larger scale to define the best practices to manage patients with acute cholangitis in the 21 st century. This study was also intended to provide a landmark epidemiological basis to solve further clinically important questions in the future studies.
Methods

Patients and data collection
This is an international multi-center retrospective observational study in Japan and Taiwan. The participating institutions were called by the Japanese Society of HepatoBiliary-Pancreatic Surgery and Taiwan Surgical Society of Gastroenterology. Each institution was accredited by those societies as teaching institutions. There were a total of 120 institutions from Japan and 10 institutions from Taiwan for participation. All consecutive patients admitted to the participating institutions who were older than 18 years of age and given a clinical diagnosis of acute cholangitis by clinicians between 1 January 2011 and 31 December 2012 were enrolled. Data were collected retrospectively by reviewing medical records. The items collected were demographic data including age, sex, Charlson Comorbidity Index, clinical symptoms, etiologies of acute cholangitis, healthcare-associated factors, history of any biliary tract diseases, previous biliary tract procedures, microbiological culture results from blood and bile, complications such as acute pancreatitis, liver abscess, and endocarditis due to acute cholangitis, and 30-day mortality as patient outcomes.
Among the enrolled patients, those who met the diagnostic criteria of acute cholangitis by TG13 [1] were statistically analyzed. Those who were not admitted during the designated study period, and who had over 95% missing items in the data collection were excluded from the analysis.
Statistical analyses were performed using IBM SPSS Statistics 20 (Armonk, NY, USA). Two-sided tests were performed to compare the distributions among the patients and a P-value <0.05 was considered significant.
Ethical approval
This study was conducted in accordance with the principles of the Declaration of Helsinki, reviewed ethically, and approved by the institutional review board of the Japanese Society of Hepato-Biliary-Pancreatic Surgery, Jichi Medical University (Number 13-54), and Mito Kyodo General Hospital, University of Tsukuba (Number 14-37). Informed consent was waived due to the retrospective nature of the study. Table 1 demonstrates demographic data on this study. The data for a total of 7,294 patients were collected by the collaborative investigators in Japan and Taiwan (Appendix S1). Among them, 797 patients who did not meet the diagnostic criteria for either definitive, or suspected acute cholangitis, were excluded from the analysis. In addition, nine patients whose data were missing over 95% of the items were also excluded from the analysis. A total of 6,433 patients were statistically analyzed in this study. There were no age differences across the severity by TG13. Patients with healthcare-associated factors were 32.7% (2,102/ 6,433), and history of any biliary tract diseases were overall 54.1% (3,480/6,433) . Before admission, a total of 40.6% of the patients had any history of biliary procedures such as cholecystectomy, biliary stent placement, and biliary enteroanastomosis ( Table 2 ). Among 6,433 patients who had data on Charlson Comorbidity Index, approximately two-thirds of the patients had the score of 5 or higher indicating multiple poor prognostic factors (Table 3) .
Results
Regarding etiologies of acute cholangitis, the majority had bile duct stones, followed by either biliary stent obstruction or biliary tumors (Table 4) . Table 5 shows all microorganisms isolated from blood cultures obtained on admission from the patients. Most frequently isolated organisms were Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca across all severity grades by TG13. Pseudomonas aeruginosa was isolated with the proportion of 1.1%, 3.1%, and 2.1%, respectively, by each TG13 severity grade. Enterococcus faecalis, Enterococcus faecium, and other Enterococcus spp. were overall 10% or less in total by each TG13 severity grade. Enterobacter cloacae and Enterobacter aerogenes were 4.9%, 4.8%, 5.2% by each TG13 severity grade. Bacteroides spp. were isolated with approximately 1% overall across the TG13 severity grades. Table 6 demonstrates microorganisms isolated from bile. Overall the number of isolated organisms was more than the ones from blood since there were more than one isolate from bile. E. coli and K. pneumonia were the most frequently isolated organisms from bile across the severity grade by TG13. Pseudomonas aeruginosa was isolated with the proportion of 2.5%, 3.5%, and 3.6%, respectively, by each TG13 severity grade. The proportions of Enterococcus spp. were relatively higher from bile than blood. From bile, Bacteroides spp. were isolated with approximately 2% across the TG13 severity grades.
Microbiological cultures were performed less than 50% of the patients (Table 7 ). Blood cultures were obtained from 3,170 out of 6,433 patients. Among them, the proportion of 40.1% had positive results. For bile cultures, 2,571 patients had bile cultures performed, and 83.4% had positive results. This was higher than blood culture results. Tables 8 and 9 show overall outcomes among the patients with acute cholangitis. The 30-day mortality due to acute cholangitis was 1.4%, 2.7%, and 5.2% by TG13 severity grade (P < 0.001). The 30-day all-cause mortality was 2.4%, 4.7%, and 8.4% by TG13 severity grade (P < 0.001).
Major complications with acute cholangitis were summarized in Table 9 . Acute pancreatitis was mild disease among 426 patients out of 6,433 (6.6%) and severe disease among 64 patients out of 6,433 (0.99%). The incidence of liver abscess was 134 out of 6,433 (2.0%) and endocarditis were 17 out of 6,433 (0.26%). The organism 
Discussion
This study demonstrated comprehensive updated demographic epidemiology, microbiology, and outcomes among patients with acute cholangitis from multiple international institutions on a larger scale for the first time. This study provides the basis for current epidemiology reflecting clinical practice with advanced technology in microbiology and endoscopic therapy. The results can be used for future comparison in epidemiological changes and clinical intervention among patients with acute cholangitis. In this study, a total of 7,294 patients with clinically diagnosed acute cholangitis were enrolled. Then 797 patients who did not meet the TG13 diagnostic criteria for acute cholangitis were excluded. This is a significant number of patients consisting of approximately 11% of the initially enrolled patients. The major reason for this result to consider was that in this study, patients were enrolled between 2011 and 2012 when TG13 were not released yet. This result suggests that clinical diagnosis had been used widely despite the existing guidelines TG07 then. The validity of the TG07 and TG13 diagnostic criteria and severity assessment for acute cholangitis has been studied [1, 19] . TG13 diagnostic criteria were improved from 82.8% (TG07) to 91.8% (TG13) in sensitivity [19] . Despite this, our study suggests that further studies are needed to investigate how those patients did not meet the criteria, and how they were clinically safely managed in clinical practice. The details of the 797 patients who did not meet the TG13 diagnostic criteria should be investigated further including which diagnostic items had not been met, and what the outcomes of those patients were. The information of these patients would help clinicians to provide better diagnosis and management for patients with acute cholangitis.
Regarding the severity distribution among the patients with acute cholangitis, Kiriyama et al. [19] reported that Patients were classified as Grade III relatively more than the previous study [19] . The most frequent etiology of acute cholangitis was bile duct stones and this was consistent with the latest epidemiological data from Japan [20] .
Microbiological data were collected both from blood and bile from multiple institutions in Japan and Taiwan. These comprehensive updated data are very useful in selecting antimicrobial agents. Antimicrobial therapy recommended by TG13 used the frame of severity grades I to III [6] . Our study demonstrated that P. aeruginosa was isolated only with the proportions of 2% to 3% across the severity grades. The populations or those who need anti-pseudomonal therapy or risk factors for antipseudomonal therapy need to be investigated in further studies. The coverage for Enterococcus spp. and Bacteroides spp. in selecting presumptive antimicrobial therapy on admission has been controversial and always in a debate in clinical practice. Our study demonstrated that blood cultures grew less proportions of Enterococcus spp. than bile cultures. TG13 recommend that Enterococcus spp. be treated for patients with community acquired acute cholangitis of TG13 Grade II or III severity grade, and healthcare-associated acute cholangitis of any severity grades [6] . Given relatively infrequently isolated Enterococcus spp., our data would support these recommendations. For the anaerobe coverage, Bacteroides spp. consisted of only 1% to 2% among the isolated microooganisms from blood and bile. Therefore, this also supports TG13 recommendations [6] that patients with a history of enterobiliary anastomosis should be treated for anaerobic organisms including Bacteroides spp. since this organism was not isolated frequently. Further analysis is warranted to see which patients had these organisms with what kind of risk factors such as a history of enterobiliary anastomosis. Regarding the outcomes among patients with acute cholangitis, our study provides updated and comprehensive data for overall mortality and complications among patients with acute cholangitis. The previously available data have been only from single or few institutions and may not have reflected true mortality for a long period of time [10, 14] . Our data demonstrated the mortalities increased along with the severity grades and this reflects validity of the TG13 severity assessment [1] .
Our study provides the incidence of liver abscess and endocarditis among patients with acute cholangitis as complications. The incidence has not been very well-known among these patients and our data will support this to avoid such complications and define better practices for patients with acute cholangitis in the near future. The details of patients with liver abscesses and endocarditis such as risk factors and microorganisms should be investigated further.
Our study has several limitations. First, this is a retrospective observational study and data collections and accuracy of the data have been limited. Second, this study did not analyze biliary drainage procedures and these therapeutic procedures should be analyzed to determine the impact on patient outcomes.
In conclusion, this study provides the first large scale comprehensive updated epidemiology, microbiology, and outcomes among patients with acute cholangitis in the 21 st century. The data will serve as the basis in defining best practices for patients with acute cholangitis. The overall mortality among patients with acute cholangitis of the Grade III severity was 8.4%. The most frequent etiology of acute cholangitis was still bile duct stones. E. coli and K. pneumoniae were the most frequently isolated organisms from blood and bile across the severity grades. Liver abscesses and infective endocarditis were documented with a small proportion of the patients, respectively, and it requires further investigation.
Appendix: author's affiliations
Harumi Gomi, Center for Global Health, Mito Kyodo General Hospital, University of Tsukuba, Ibaraki, Japan; Tadahiro 
